Trajectories of Interferon-Gamma Release Assay Results Over 2 Years in Independent Cohorts From China, South Africa, Tanzania, and the United States
CHEST · 2025-07 · 168 (1) · 33-42
DOI: 10.1016/j.chest.2025.01.031 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift CHEST, 2025-07. Verfasst von Cheng Chen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, Jiangsu Province, China. Hauptthemen laut MEDLINE: Interferon-gamma Release Tests, Mycobacterium tuberculosis, Latent Tuberculosis, Tuberculosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, Boston University, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: There is an ongoing debate about whether clearance of Mycobacterium tuberculosis infection occurs and at what magnitude. Recent studies quantifying "uncertainty zones" of interferon-gamma release assays (IGRAs) provide a more stringent estimate of reversion. RESEARCH QUESTION: When accounting for uncertainty zones through stringent cutoffs, what are the trajectories of IGRAs results over 2 years of testing? STUDY DESIGN AND METHODS: Five cohorts from South Africa, China, Tanzania, and the United States tested with an IGRA 3 or more times were followed up for stringent conversion and reversion. The annual risk of IGRA reversion was assessed following an IGRA conversion and among those with baseline positivity. RESULTS: A total of 26,596 IGRA measurements were taken over 13,593 years of follow-up (Nparticipants = 7,683). Stringent reversion at year 2 following stringent conversion at year 1 varied between cohorts, occurring in 48% (43/90) for Wantai, 37% (22/59) for QuantiFERON, and 17% (2/12) for T-SPOT.TB, respectively. In the US cohorts, stringent reversion at year 1 following stringent conversion at 6 months was 58% (15 of 26) for QuantiFERON and 18% (12 of 60) for T-SPOT.TB. Stringent reversion at 1 year following baseline positivity occurred in 12% (47 of 404) for Wantai, 21% (10 of 48) for QuantiFERON, and 44% for T-SPOT.TB (45 of 102). In one cohort from China (N = 399; age range, 59 years [interquartile range, 48-67 years]), IGRA reversion was more common in younger participants (adjusted OR [aOR], 0.95; 95% CI, 0.93-0.97) and those without recent close TB exposure (aOR, 0.35 [95% CI, 0.11-1.03] in South Africa; aOR, 0.10 [95% CI, 0.01-0.61] in China). INTERPRETATION: These results suggest high annual rates of IGRA reversion, even with the use of uncertainty zones; reversion rates decreased over time from exposure and at older ages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing, Jiangsu Province, China.
- Department of Chronic Communicable Diseases, Center for Disease Control and Prevention of Yancheng, Yancheng, China.
- Department of Epidemiology, School of Public Health, Boston University, Boston, MA; Department of Biostatistics, School of Public Health, Boston University, Boston, MA; Department of Global Health, School of Public Heal…
- Department of Community Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
- South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine (IDM), and Department of Pathology, University of Cape Town, Cape Town, South Africa.
- Dartmouth International Vaccine Initiative, Geisel School of Medicine at Dartmouth, Hanover, NH.
Förderung
- National Institute of Allergy and Infectious Diseases
- Boston University
- National Institutes of Health
- Boston Medical Center
Zitieren
APA
Chen, C., Xue, H., Horsburgh, C. R., Amour, M., Hatherill, M., Tameris, M., von Reyn, C. F., Rees, C., Shen, Y., McShane, H., García-Basteiro, A. L., Liu, D., Wang, Y., Nathavitharana, R. R., Graviss, E. A., Shao, Y., Liu, Q., Lu, W., Zhu, L., & Martinez, L. (2025). Trajectories of Interferon-Gamma Release Assay Results Over 2 Years in Independent Cohorts From China, South Africa, Tanzania, and the United States. CHEST, 168(1), 33-42. https://doi.org/10.1016/j.chest.2025.01.031
Vancouver
Chen C, Xue H, Horsburgh CR, Amour M, Hatherill M, Tameris M, et al. Trajectories of Interferon-Gamma Release Assay Results Over 2 Years in Independent Cohorts From China, South Africa, Tanzania, and the United States. CHEST. 2025;168(1):33-42. doi:10.1016/j.chest.2025.01.031
BibTeX
@article{Chen2025,
author = {Chen, Cheng and Xue, Hao and Horsburgh, C Robert and Amour, Maryam and Hatherill, Mark and Tameris, Michele and von Reyn, C Fordham and Rees, Christiaan and Shen, Ye and McShane, Helen and García-Basteiro, Alberto L and Liu, Donglin and Wang, Yijun and Nathavitharana, Ruvandhi R and Graviss, Edward A and Shao, Yan and Liu, Qiao and Lu, Wei and Zhu, Limei and Martinez, Leonardo},
title = {Trajectories of Interferon-Gamma Release Assay Results Over 2 Years in Independent Cohorts From China, South Africa, Tanzania, and the United States},
journal = {CHEST},
year = {2025},
volume = {168},
number = {1},
pages = {33--42},
doi = {10.1016/j.chest.2025.01.031}
}
EUVIMED